Abstract 1612P
Background
Patient centred outcome measures (PCOMs) are increasingly used to structure proactive symptom assessment and help centre care around the specific needs of the patient. This study aimed to review the use of PCOMs as part of the routine care of inpatients reviewed by the integrated palliative care team in a specialist cancer centre.
Methods
Anonymised electronic palliative care PCOM data were retrieved for inpatients between 7/4/2021 to 31/01/2023, including Integrated Palliative Outcome Scale (IPOS), ECOG performance status, Australian Karnofsky Performance Status (AKPS) and Phase of Illness (POI). Descriptive statistics were used to define the complexity of palliative care needs based on IPOS, PS and POI. The effectiveness of the integrated palliative care service was evaluated by examining the difference between PCOM at initial and follow up assessment.
Results
Digital PCOM records for 1115 episodes of inpatient care were included, of which 391 had follow up data. On initial assessment 63% (703) patients had ECOG PS of 3 or 4 and 77% (864) had AKPS of less than 70. The most prevalent physical symptoms were weakness (84%, 1265), pain (80.7%, 1215), and poor mobility (72.3%, 1089). The most prevalent psychosocial symptom was family or friends feeling anxious or worried (85.8%, 1292). 83% (1250) had at least one palliative care need of severe or overwhelming intensity on initial assessment. 67.5% (753) were in an unstable POI on initial assessment, requiring urgent input. On follow up 92% (328) patients were in a stable, deteriorating or dying POI with no change to the care plan required. In patients with initial moderate to overwhelming symptoms, pain improved in 74%, nausea improved in 84%, vomiting improved in 93%, and constipation improved in 68% at follow up.
Conclusions
The high prevalence of physical and psychosocial symptoms demonstrates the complexity of needs and provides evidence of the requirement for integration of specialist palliative care services in cancer centres. The improvement in symptom scores between initial and follow up assessment demonstrates the effectiveness of integrated palliative care for cancer centre inpatients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05